Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Food Allergy Peanut Clear all
Completed Phase 3 Interventional Results available

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

HAL-MPE1 Safety and Tolerability Study

NCT02991885
View directory record Official record
Conditions
Peanut Allergy
Interventions
HAL-MPE1, HAL-MPE1 placebo
Biological · Drug
Lead sponsor
HAL Allergy
Industry
Eligibility
5 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy, Omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

NCT03907397
View directory record Official record
Conditions
Food Allergy, Peanut Allergy
Interventions
Peanut Protein, Continued peanut avoidance
Biological · Other
Lead sponsor
Scott Sicherer
Other
Eligibility
4 Years to 14 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
View directory record Official record
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 12, 2026, 1:19 PM EDT
Terminated Phase 1 Interventional

Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

NCT04950504
View directory record Official record
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Scottsdale, Arizona • Mountain View, California • Rolling Hills Estates, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Anxiety About Casual Exposure to Food Allergens

NCT03349047
View directory record Official record
Conditions
Food Allergy
Interventions
Behavioral intervention group, Education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
108 Months to 210 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Immunotherapy for Peanut Allergy

NCT00429429
View directory record Official record
Conditions
Allergy
Interventions
Sublingual immunotherapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 35 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Oral Peanut Immunotherapy

NCT01324401
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour OIT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 12, 2026, 1:19 PM EDT
Recruiting No phase listed Observational

Study of Oral Food Challenge Biomarkers (SAFER)

NCT07279467
View directory record Official record
Conditions
Allergy
Interventions
Oral Food Challenge (OFC): Peanut Protein
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Recruiting Phase 3 Interventional

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

NCT07768371
View directory record Official record
Conditions
IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
View directory record Official record
Conditions
Peanut Allergy
Interventions
Prebiotic, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

NCT01084174
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions
Peanut powder, Peanut extract, Placebo extract, Placebo powder
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anaphylaxis With Acalabrutinib

NCT05038904
View directory record Official record
Conditions
Food Allergy, Food Allergy Peanut
Interventions
Acalabrutinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 12, 2026, 1:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Open-label Extension Study of ADP101

NCT05243719
View directory record Official record
Conditions
Food Allergy
Interventions
ADP101
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 57 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Active, not recruiting Phase 3 Interventional

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

NCT03013517
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250µg
Drug
Lead sponsor
DBV Technologies
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dupilumab, Placebo matching dupilumab, AR101
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients

NCT03463135
View directory record Official record
Conditions
Food Allergy
Interventions
Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE), Placebo for GLA, Placebo for SLIT PE
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Little Rock, Arkansas • Mission Viejo, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

NCT00580606
View directory record Official record
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 12, 2026, 1:19 PM EDT
Active, not recruiting No phase listed Observational

Food Oral Immunotherapy for Peanut Allergy

NCT04222491
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 12, 2026, 1:19 PM EDT